Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of concurrent chemoradiotherapy plus recombinant human endostatin in cervical cancer
ChiCTR1900023144Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in Cervical Cancer (CC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 2-year progression-free survival. Started Dec 2018; status: recruiting.
02
Drugs
endostar
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900023144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023144.